IL251759B - Compositions and methods for treating insomnia - Google Patents

Compositions and methods for treating insomnia

Info

Publication number
IL251759B
IL251759B IL251759A IL25175917A IL251759B IL 251759 B IL251759 B IL 251759B IL 251759 A IL251759 A IL 251759A IL 25175917 A IL25175917 A IL 25175917A IL 251759 B IL251759 B IL 251759B
Authority
IL
Israel
Prior art keywords
preparations
methods
treating insomnia
insomnia
treating
Prior art date
Application number
IL251759A
Other languages
English (en)
Hebrew (he)
Other versions
IL251759A0 (en
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of IL251759A0 publication Critical patent/IL251759A0/en
Publication of IL251759B publication Critical patent/IL251759B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
IL251759A 2014-10-23 2017-04-18 Compositions and methods for treating insomnia IL251759B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462067443P 2014-10-23 2014-10-23
PCT/JP2015/080304 WO2016063995A1 (en) 2014-10-23 2015-10-21 Compositions and methods for treating insomnia

Publications (2)

Publication Number Publication Date
IL251759A0 IL251759A0 (en) 2017-06-29
IL251759B true IL251759B (en) 2021-01-31

Family

ID=55761025

Family Applications (1)

Application Number Title Priority Date Filing Date
IL251759A IL251759B (en) 2014-10-23 2017-04-18 Compositions and methods for treating insomnia

Country Status (14)

Country Link
US (3) US10188652B2 (OSRAM)
EP (1) EP3209298B1 (OSRAM)
JP (1) JP6659681B2 (OSRAM)
KR (1) KR102444608B1 (OSRAM)
CN (1) CN107810006B (OSRAM)
AU (1) AU2015336463B2 (OSRAM)
BR (1) BR112017007063A2 (OSRAM)
CA (1) CA2964504C (OSRAM)
ES (1) ES2843952T3 (OSRAM)
IL (1) IL251759B (OSRAM)
MX (1) MX376164B (OSRAM)
RU (1) RU2703297C2 (OSRAM)
SG (2) SG11201703064WA (OSRAM)
WO (1) WO2016063995A1 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016063995A1 (en) 2014-10-23 2016-04-28 Eisai R&D Management Co., Ltd. Compositions and methods for treating insomnia
CN109640998A (zh) * 2016-05-12 2019-04-16 卫材研究发展管理有限公司 治疗昼夜节律性睡眠障碍的方法
EP4613333A3 (en) 2016-08-10 2025-10-29 F. Hoffmann-La Roche AG Pharmaceutical compositions comprising akt protein kinase inhibitors
JP7179049B2 (ja) 2017-08-01 2022-11-28 ベルゲン ファーマシューティカル、 エルエルシー オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途
MX2021005967A (es) 2018-11-21 2021-10-13 Tremeau Pharmaceuticals Inc Formas purificadas de rofecoxib, métodos de fabricación y uso.
JP2022538170A (ja) * 2019-06-26 2022-08-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 睡眠問題の治療のためのレンボレキサント
WO2020263253A1 (en) * 2019-06-26 2020-12-30 Moline Margaret Lemborexant for treating sleep issues
KR20220027981A (ko) * 2019-06-26 2022-03-08 에자이 알앤드디 매니지먼트 가부시키가이샤 수면 문제를 치료하기 위한 렘보렉산트
BR112022004587A2 (pt) * 2019-09-13 2022-06-14 Takeda Pharmaceuticals Co Métodos para tratar narcolepsia tipo 1, diminuir eventos tipo cataplexia, aumentar concentração de cálcio intracelular, aumentar latência de sono em manutenção de teste de insônia, melhorar classificação de escaça de sonolência de karolinska, tratar uma doença associada a nível de orexina reduzido, aumentar alerta, melhorar classificação de escala de sonolência epworth, e, composição farmacêutica
CN114502167A (zh) * 2019-09-13 2022-05-13 卫材R&D管理有限公司 用于治疗失眠的药物组合物
JP2023508011A (ja) * 2019-12-20 2023-02-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 不眠症を治療するためのレンボレキサントの使用
JPWO2021145373A1 (OSRAM) * 2020-01-16 2021-07-22
BR112022020924A2 (pt) 2020-04-19 2023-02-14 Idorsia Pharmaceuticals Ltd Métodos de tratamento de um transtorno do sono, a sonolência diurna em um indivíduo, a insônia, e, daridorexante na forma de sal livre ou farmaceuticamente aceitável
CN111450076A (zh) * 2020-05-25 2020-07-28 安徽省逸欣铭医药科技有限公司 一种Lemborexant软胶囊组合物及其制备方法
CA3266968A1 (en) 2022-09-23 2024-03-28 Eisai R&D Management Co., Ltd. Methods of reducing neurodegeneration associated with neurodegenerative diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120095031A1 (en) * 2010-09-22 2012-04-19 Eisai R&D Management Co., Ltd. Cyclopropane compound

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06328057A (ja) 1993-05-26 1994-11-29 Sanyo Electric Co Ltd 厨芥処理装置
CA2220036A1 (en) 1995-05-05 1996-11-07 Human Genome Sciences, Inc. Human neuropeptide receptor
US6001963A (en) 1996-12-17 1999-12-14 Smithkline Beecham Corporation Ligands of the neuropeptide receptor HFGAN72
US6309854B1 (en) 1996-12-17 2001-10-30 Smithkline Beecham Corporation Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
US5935814A (en) 1997-04-30 1999-08-10 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72Y receptor
US6020157A (en) 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
PT1751111E (pt) 2004-03-01 2015-04-01 Actelion Pharmaceuticals Ltd Derivados de 1,2,3,4-tetrahidroisoquinolina substituída
MX2007003377A (es) 2004-09-23 2007-05-10 Pfizer Prod Inc Agonistas del receptor de trombopoyetina.
JP2006328057A (ja) 2005-04-25 2006-12-07 Eisai R & D Management Co Ltd 抗不安薬及びそのスクリーニング方法
US20090082394A1 (en) 2006-03-15 2009-03-26 Actelion Pharmaceuticals, Ltd. Tetrahydroisoquinoline Derivatives to Enhance Memory Function
WO2007129188A1 (en) 2006-05-10 2007-11-15 Pfizer Japan Inc. Cyclopropanecarboxamide compound
US7691893B2 (en) 2006-09-11 2010-04-06 Glaxo Group Limited Chemical compounds
CL2007002809A1 (es) 2006-09-29 2008-04-18 Actelion Pharmaceuticals Ltd Compuestos derivados de 3-aza biciclo [3.1.0]hexano; y su uso en el tratamiento de enfermedades tales como desordenes psicoticos y de ansiedad, desordenes del sueno, uso y abuso de sustancias psicoactivas, demencia y deterioro de funciones cognitivas
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
CL2007003827A1 (es) 2006-12-28 2008-09-26 Actelion Pharmaceuticals Ltd Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras.
MX2010002419A (es) 2007-09-21 2010-03-30 Sanofi Aventis (ciclopropilfenil) feniloxamidas, metodo para su produccion y uso como un medicamento.
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
WO2011098955A1 (en) * 2010-02-15 2011-08-18 Koninklijke Philips Electronics N.V. Mitigation of control channel interference
US20120165339A1 (en) 2010-12-22 2012-06-28 Eisai R&D Management Co., Ltd. Cyclopropane derivatives
WO2016063995A1 (en) 2014-10-23 2016-04-28 Eisai R&D Management Co., Ltd. Compositions and methods for treating insomnia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120095031A1 (en) * 2010-09-22 2012-04-19 Eisai R&D Management Co., Ltd. Cyclopropane compound

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PAOLO BETTICA ET AL, PHASE I STUDIES ON THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SB-649868, A NOVEL DUAL OREXIN RECEPTOR ANTAGONIST, 5 July 2011 (2011-07-05) *

Also Published As

Publication number Publication date
CN107810006A (zh) 2018-03-16
WO2016063995A1 (en) 2016-04-28
JP2017531683A (ja) 2017-10-26
EP3209298A4 (en) 2018-06-20
US20170252342A1 (en) 2017-09-07
RU2703297C2 (ru) 2019-10-16
AU2015336463A1 (en) 2017-05-04
KR102444608B1 (ko) 2022-09-20
ES2843952T3 (es) 2021-07-21
US20200268754A1 (en) 2020-08-27
CN107810006B (zh) 2021-03-30
EP3209298A1 (en) 2017-08-30
US10702529B2 (en) 2020-07-07
IL251759A0 (en) 2017-06-29
MX376164B (es) 2025-03-07
US11026944B2 (en) 2021-06-08
CA2964504C (en) 2022-08-23
CA2964504A1 (en) 2016-04-28
SG11201703064WA (en) 2017-05-30
US10188652B2 (en) 2019-01-29
SG10202007759RA (en) 2020-09-29
JP6659681B2 (ja) 2020-03-04
MX2017004950A (es) 2018-01-16
US20190201399A1 (en) 2019-07-04
BR112017007063A2 (pt) 2018-02-14
EP3209298B1 (en) 2020-12-02
KR20170068478A (ko) 2017-06-19
AU2015336463B2 (en) 2020-06-18
RU2017112308A3 (OSRAM) 2019-05-08
RU2017112308A (ru) 2018-11-26

Similar Documents

Publication Publication Date Title
IL280209A (en) Compositions and methods for the treatment of meibomian gland dysfunction
IL282570B (en) Methods and devices for treating pulmonary edema
IL296080B1 (en) Method for treating cancer
IL282372A (en) Haploid induction compositions and methods for use therefor
IL266458A (en) Equipment and methods for treating objects
IL258955A (en) Compositions and methods for treatment of cancer
IL251759B (en) Compositions and methods for treating insomnia
IL257105A (en) Modified cells and methods of therapy
IL255261A0 (en) Methods for treating cancer
IL251215B (en) Cannabinoid composition and method for treating pain
IL255615A (en) Use of cannabis to treat fibromyalgia, methods and compositions thereof
DK3215147T3 (da) Neurodæmpende norketamin-forbindelser og fremgangsmåder
EP3205103C0 (en) INTER AND INTRA UNIFICATION BLOCK COPY
MA40933A (fr) Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
GB201404470D0 (en) Therapeutic methods and materials
BR112016027102A2 (pt) método e aparelho
HUE054673T2 (hu) Rák kezelésére szolgáló eljárások és készítmények
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
KR20180084747A (ko) Galgt2 유전자 치료 방법 및 물질
IL246607B (en) Improved cell compositions and methods for cancer therapy
EP3302207A4 (en) Surface treatment apparatuses and methods
PL3393468T3 (pl) Metody leczenia niedoboru odporności
IL268570B (en) Oligonucleotide compositions and methods of making the same
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
GB201416293D0 (en) Methods and preparations

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed